Stockwinners Market Radar for October 25, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT Saverone 2014 Ltd. trading halted, news pending

18:56 EDT Investors behind Territorial Bancorp proposal send disclosure to board - Investors behind a proposal submitted on August 26 to the Board of Directors of Territorial Bancorp have disclosed information about themselves in an addendum sent to Territorial's outside counsel. The investors have offered repeatedly since late August to engage with the Board and advance their proposal toward a binding agreement that they believe will be better for all Territorial stakeholders. The Addendum offers additional details about the seven seasoned bank investors backing the proposal, whose individual expressions of interest in acquiring Territorial shares total $134M. That is $26M more than the amount required to tender for 100% of Territorial's shares at a price of $12.50 per share and nearly $80M more than the amount required to tender for 51% of Territorial's shares, a new reduced minimum threshold the investors have committed to in the Addendum. The investors collectively manage $3.4B in investor capital and comprise a mix of funds, family offices and private investors who have executed hundreds of transactions like this. Two of the investors have opted to remain anonymous due to the Board's history of aggressive and misleading public statements - detailed information about them is nevertheless provided in the Addendum. "Territorial has perpetuated a false narrative about the relative risks of these two transactions. Territorial's shareholders and Board should be comforted by the strong, oversubscribed interest in this transaction among the seven experienced investors who are backing this proposal," said Jason Blumberg, Managing Member of Blue Hill Advisors. "Our proposal clearly exceeds the threshold of 'reasonably likely to lead to a Superior Proposal,' and the Board should engage immediately." Thus far, however, the investors have been stymied by the Board's refusal to engage on any level. The Board has declined every overture, citing Territorial's merger agreement with Hope which prohibits engagement until the Board determines that a proposal is "reasonably likely to lead to a Superior Offer." The investors firmly believe they have always cleared the "reasonably likely" hurdle and opted to send the Addendum to put to rest any questions about the viability of their offer. The investors are now calling on the Board to uphold its fiduciary duty to shareholders and explore a potentially superior proposal that values Territorial at a 25% premium to the current value of the consideration shareholders would receive in a sale to Hope. The Board should stop provoking the investors with ludicrous demands - for example, suggesting that Blue Hill Advisors, one of the investors behind the proposal, should make a sight-unseen "legally binding 'hell or highwater' commitment" - and instead engage quickly. Blumberg concluded, "Territorial shareholders should continue voting AGAINST the sale to Hope to force the Board to the table. The special meeting can be postponed one more time if Territorial cannot achieve the requisite shareholder support on November 6. The Board can use the extra time between now and the next meeting to give the investors access to information to finalize this superior proposal."

17:35 EDT Tevogen provides more guidance on ExacTcell technology - Tevogen Bio provided additional guidance on the first clinical product of the company's proprietary ExacTcell technology, TVGN 489, designed to treat SARS-CoV-2 infections in immunocompromised oncology patients, and a subgroup of patients with post-acute sequelae of SARS-CoV-2. Tevogen Bio's recently shared forecast reflects its business plan of market entry by the end of 2026. "The rapid and cost-effective development of TVGN 489, achieved at a fraction of industry norms, strengthens my confidence in Tevogen's innovative business model," remarked Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio, Nobel Peace Prize nominee, inventor of ExacTcell. "The positive clinical trial underscores TVGN 489's potential, and it is my personal commitment that the company will do everything in its power to speed up the development process. I am pleased that the company was able to make progress to bridge any information gap and look forward to sharing other achievements in the coming weeks, particularly on the progress of Tevogen.AI."

17:30 EDT Onyx Acquisition Co I trading resumes

17:24 EDT RTX awarded $900M Missile Defense Agency contract modification - Raytheon was awarded an estimated $900M contract modification for a non-competitive two-year extension of an indefinite-delivery/indefinite-quantity contract that will increase the contract ceiling from $1.7B to $2.6B. The current contract was the result of a sole-source acquisition. Under this contract extension, Raytheon will continue operations and sustainment support of the Sea-based, X-band Radar and the 13 Army-Navy Transportable Radar Surveillance and Control Model 2 radar systems utilizing a combination of cost-plus-incentive-fee, cost-plus-fixed-fee, and firm-fixed-price contract line items. Associated task order extensions reflecting the increase are also being awarded. The work will be performed in Woburn, Massachusetts, and at multiple radar sites inside and outside of the continental U.S. The contract modification will extend the current ordering period an additional two years from October 31 to October 31, 2026, resulting in an overall contract ordering period of nine years. FY25 and FY26 operations and maintenance, and research, development, test and evaluation funds will be obligated for this effort via task order modifications. The Missile Defense Agency is the contracting activity.

17:03 EDT Onyx Acquisition Co. I to redeem public shares, intends to delist - Onyx Acquisition Co. I. announced that it will redeem all of its outstanding Class A ordinary shares included as part of the units issued in its initial public offering, effective as of the close of business on November 13, because the company will not consummate an initial business combination within the time period required by its amended and restated memorandum and articles of association. Accordingly, the company will not be seeking a further extension as contemplated by the preliminary proxy statement filed with the SEC on October 11. The per-share redemption price for the Public Shares is expected to be approximately $11.42. Because the company will not consummate an initial business combination within the periods required under its Articles and Nasdaq Listing Rule IM 5101-2, the company intends to file a Form 25 with the Commission on November 4 in order to delist the company's securities from the Nasdaq Capital Market. The company thereafter expects to file a Form 15 with the Commission to terminate the registration of the company's securities under the Securities Exchange Act of 1934, as amended.

16:34 EDT U-BX Technology receives noncompliance letter from Nasdaq - U-BX Technology announced that it has received written notifications from Nasdaq on October 21. The notification letters advised the company that for the last 31 consecutive business days, the minimum closing bid price per share for the company's ordinary shares was below the $1.00 per share requirement for continued listing under Nasdaq Listing Rule 5550(a)(2). The notification letters also advised the company that for the last 30 consecutive business days, the minimum Market Value of Listed Securities, or MVLS, of the company was below the $35M requirement for continued listing under Nasdaq Listing Rule 5550(b)(2).

16:31 EDT Stronghold Digital Mining CFO Matthew Smith to resign - Stronghold Digital Mining announced that Chief Financial Officer Matthew Smith will resign from his position, effective November 15, 2024, after the company files its Quarterly Report on Form 10-Q for the third quarter of 2024. Smith will also step down from the company's Board of Directors at that time. Smith's resignation was not due to any disagreement with the company on any matter relating to the Company's operations, policies or practices, including accounting principles and practices. Following his departure, the company intends to retain Smith as a consultant to assist with the transition of his responsibilities for a period of time. Currently, the company does not intend to fill the vacancy on the Board that will be created following the effective date of Smith's resignation.

16:20 EDT Philip Morris exec De Wilde sells 25,000 common shares - In a regulatory filing, Philip Morris executive Frederic De Wilde disclosed the sale of 25,000 common shares of the company on October 23 at a price of $130.96 per share.

16:08 EDT Peoples Financial CEO Craig Best to step down, Gerard Champi to succeed - On October 25, the board of directors of Peoples Financial Services and Craig Best mutually agreed that Best would cease serving as CEO and director of the company and its banking subsidiary, Peoples Security Bank and Trust Company, effective December 31. The company consummated a merger with FNCB Bancorp on July 1, and it had been contemplated that Best would remain as an officer of the company and the Bank through the first anniversary of the merger. Given the progress made in the integration of the two companies and the successful completion of the Bank's system conversion on October 15, the parties determined that Best was able to leave at the end of this year. Gerard Champi, President of the company and the Bank, will succeed Best as CEO of the company and the Bank, and Thomas Tulaney, COO of the company and the Bank, will succeed Champi as President of the company and the Bank.

16:06 EDT MDJM Ltd receives Nasdaq notification regarding bid price deficiency - MDJM announced that the company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC on October 23, 2024, notifying the company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the company's ordinary shares for the 30 consecutive business days from September 11, 2024 to October 22, 2024, the company no longer meets the minimum bid price requirement.

15:08 EDT Prime Medicine treatment of retinal dystrophy granted orphan designation - Prime Medicine's treatment of retinal dystrophy due to USH2A gene mutations was granted FDA orphan designation, according to a post to the agency's website. Reference Link

14:53 EDT Spar Group stockholders approve merger with Highwire Capital - Spar Group announced that its stockholders approved at a special meeting the acquisition of Spar Group by Highwire Capital. Under the terms of the Agreement and Plan of Merger, dated as of August 30, by and among Spar Group, Highwire Capital and Highwire Merger Co. I, Inc., a wholly owned subsidiary of Highwire Capital, SGRP stockholders will receive $2.50 in cash per share of common stock. Spar Group expects to announce the consummation of the transaction later in the fourth quarter of 2024, subject to the satisfaction of certain customary closing conditions set forth in the merger agreement. Upon completion of the transaction, Spar Group will become a privately held company, and its stock will no longer be traded on Nasdaq.

13:55 EDT Entergy boosts quarterly dividend to $1.20 from $1.13 - Entergy's board declared a quarterly dividend payment of $1.20 per share, an increase of 7c per share, on the company's common stock. The dividend is payable December 2, to shareholders of record as of November 13.

13:08 EDT ShiftPixy trading resumes

13:01 EDT Baker Hughes reports U.S. rig count unchanged at 585 rigs - Baker Hughes reports that the U.S. rig count is unchanged from last week at 585 with oil rigs down 2 to 480, gas rigs up 2 to 101 and miscellaneous rigs unchanged at 4. The U.S. Rig Count is down 40 rigs from last year's count of 625 with oil rigs down 24, gas rigs down 16 and miscellaneous rigs unchanged. The U.S. Offshore Rig Count is down 2 to 16, down 8 year-over-year. The Canada Rig Count is down 1 from last week to 216, with oil rigs down 3 to 150, gas rigs up 2 to 66 and miscellaneous rigs unchanged at 0. The Canada Rig Count is up 20 from last year's count of 196, with oil rigs up 28, gas rigs down 8 and miscellaneous rigs unchanged.

12:59 EDT Evolv falls 42% after delaying Q3 report, saying board conducting investigation - Shares of Evolv Technologies are down $1.72, or 42%, to $2.38 after the company delayed the filing of its Q3 report after an ad hoc committee of the board determined that certain financial statements should not be relied upon.

12:56 EDT Evolv delays Q3 release, says certain prior financials shouldn't be relied upon - Earlier, Evolv Technology announced that shareholders and others should not rely upon certain of the company's previously issued financial statements and that it will delay filing its Quarterly Report on Form 10-Q for the period ended September 30. "An ad hoc committee of independent directors of the Board of Directors of the Company, under the direction of the Board, is conducting an internal investigation that is focused on the Company's sales practices, including whether certain sales of products and subscriptions to channel partners and end users were subject to extra-contractual terms and conditions that impacted revenue recognition and other metrics, and if so, when senior Company personnel became aware of these issues. While the committee's investigation is ongoing, the committee has made a preliminary determination that certain sales, including sales to one of its largest channel partners, were subject to extra-contractual terms and conditions, some of which were not shared with the Company's accounting personnel, and that certain Company personnel engaged in misconduct in connection with those transactions. Furthermore, these extra-contractual terms and conditions were withheld from the Company's Audit Committee of the Board and the Company's independent registered public accounting firm, PricewaterhouseCoopers LLP," the company stated. The Board commented, "We recognize the importance of timely and accurate financial disclosures and are working expeditiously to conclude our thorough investigation. The Board is committed to taking whatever remedial actions are necessary, so that the Company can provide reliable information to our key stakeholders. The fundamentals of our business remain strong. We are seeing demand for our products and services that is in line with our internal forecasts and consistent with our long-term expectations of advancing our distribution model and achieving the Rule of 40." The company added that it has self-reported these issues to the Division of Enforcement of the U.S. Securities and Exchange Commission, which had been conducting a previously disclosed and unrelated investigation, and said that the company is "continuing to cooperate with the SEC investigation."

12:11 EDT Beasley Broadcast trading halted, volatility trading pause

12:02 EDT Hubbell board raises quarterly dividend 8% to $1.32 per share - The Board of Directors of Hubbell declared a 8% increase in its common stock dividend rate. The new annual payment of $5.28 per share, or $1.32 per quarter, compares to the former rate of $4.88 per share, or $1.22 per quarter. The dividend will be paid on December 16, 2024 to shareholders of record on November 29, 2024.

12:00 EDT Daqo New Energy rises 16.5% - Daqo New Energy is up 16.5%, or $3.64 to $25.64.

12:00 EDT Joby Aviation falls -12.8% - Joby Aviation is down -12.8%, or -78c to $5.26.

12:00 EDT Capri Holdings falls -47.3% - Capri Holdings is down -47.3%, or -$19.68 to $21.92.

11:30 EDT Iterum Therapeutics PLC trading resumes

11:19 EDT Vale reaches settlement with Brazil for full reparation of Fundao dam collapse - Vale (VALE) said that Samarco, BHP Billiton Brasil (BHP) and Vale, together with the Brazilian Federal Government, the State Governments of Minas Gerais and Espirito Santo, the Federal and State Public Prosecutors' and Public Defenders' Offices and other Brazilian public entities reached today a definitive and substantial settlement of claims related to the Fundao dam collapse in Mariana, Minas Gerais, Brazil, on November 5, 2015. "The Definitive Settlement enabled a mutually beneficial resolution for all Parties under fair and effective terms, while creating definitiveness and legal certainty. It is the result of a high-level mediation process conducted by the Brazilian Federal Court of Appeals of the 6th Region, with open dialogue and transparency. The engagement of Brazilian authorities and public entities ensured legitimacy to the settlement, which was supported by social, environmental and technical criteria. This important agreement also reinforces our commitment to Brazilian society and to a better future for the people, communities and the environment." said Gustavo Pimenta, Vale's CEO. The Definitive Settlement provides for a total financial value of approximately 170B reais, comprising past and future obligations, to serve the people, communities and the environment impacted by the dam failure. It sets three main lines of obligations. Funds will support several compensation fronts, ensuring substantial resources for improvements in health, sanitation, fishing activities and community funding, and a dedicated approach to indigenous and traditional communities, and municipalities. Samarco will execute certain obligations, including a voluntary-based, simplified individual indemnification system, measures towards the Doce River environmental recovery and the completion of community resettlements, which already reached around 94% of total cases to be delivered as of September 30, 2024. Hence, part of the Renova Foundation's 42 programs will be gradually transferred to Samarco or the authorities, while the remaining programs will be closed. The Renova Foundation's governance body will cease on signing.

11:08 EDT McDonald's drops 2% to $296.35 after CDC reports 26 new E. coli cases

11:06 EDT Iterum Therapeutics announces FDA approval of Orlynvah - Iterum Therapeutics plc announced that the U.S. Food and Drug Administration has approved Iterum's new drug application for Orlynvah for the treatment of uncomplicated urinary tract infections, or uUTIs, caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options. "This is the first approved indication for Orlynvah and the first FDA-approved product for Iterum," the company stated. "We are so pleased to have achieved this historic milestone and would like to thank all the patients, investigators, Iterum colleagues and Iterum consultants and vendors who participated in the development of Orlynvah. Orlynvah offers new hope for patients suffering from difficult-to-treat uUTIs. The introduction of novel products, like Orlynvah, is an important way to combat antimicrobial resistance to other approved oral agents and offers a potential solution to patients and physicians," said Corey Fishman, Iterum's Chief Executive Officer. "As the first oral penem approved in the U.S., Orlynvah offers an excellent alternative treatment option for appropriate patients in the underserved uUTI market. With FDA approval and a clear label, we will renew our efforts to achieve a strategic transaction involving Orlynvah with the goal of maximizing value for our stakeholders."

10:58 EDT FDA posts approval of Iterum Therapeutics' Orlynvah - Reference Link

10:32 EDT RDE announces rebranding with name change to Giftify - RDE announced its corporate rebranding to Giftify, which was approved by shareholders and officially becomes effective on October 28th. The company said, "The new name will optimize the company's brand portfolio, reduce complexities, further underscore its evolution to deliver solutions beyond its traditional Restaurant.com offering and provides the Company broader options for expansion in the future."

10:31 EDT Rayonier's Jesup facility resumes full production ahead of schedule - Rayonier Advanced Materials announced that its Jesup, Georgia facility has fully resumed operations ahead of schedule, following an isolated fire on October 11. All production lines have returned to producing on-grade material at full capacity. The Company continues to assess the financial impact of the incident, including potential insurance recoveries, and will provide further updates during its third-quarter earnings call on November 6.

10:24 EDT Vale trading halted, news pending

10:19 EDT Orangekloud CFO Shally Ang resigns, Toh Puay-Yong to succeed - Orangekloud Technology announced the appointment of Toh Puay-Yong as CFO, replacing Ms. Shally Ang, who had held that position since February 2023 and is resigning due to personal reasons. Toh will be responsible for financial and management reporting, corporate services, and company compliance. Since 2017, Toh has served the company in various capacities, including finance, M&A, strategic management, and HR development. He covered Orangekloud's CFO duties from mid-February to early June while Ang was on maternity leave. Toh has also been a management consultant advising regional enterprises, including MSC Consulting, on financial management, business strategy, HR development, and M&A and business valuation.

10:04 EDT Armlogi Holding Corp trading resumes

10:00 EDT Joby Aviation falls -14.5% - Joby Aviation is down -14.5%, or -88c to $5.17.

10:00 EDT Capri Holdings falls -45.0% - Capri Holdings is down -45.0%, or -$18.72 to $22.88.

10:00 EDT Daqo New Energy rises 18.1% - Daqo New Energy is up 18.1%, or $3.98 to $25.98.

09:54 EDT Armlogi Holding Corp trading halted, volatility trading pause

09:47 EDT World Kinect falls -13.3% - World Kinect is down -13.3%, or -$4.17 to $27.17.

09:47 EDT Capri Holdings falls -44.8% - Capri Holdings is down -44.8%, or -$18.64 to $22.96.

09:47 EDT Centene rises 12.7% - Centene is up 12.7%, or $7.86 to $69.47.

09:46 EDT Alphabet announces $5.6B investment round, led by Alphabet - Waymo announce that it closed an "oversubscribed" investment round of $5.6B, led by Alphabet (GOOG, GOOGL), with continued participation from Andreessen Horowitz, Fidelity, Perry Creek, Silver Lake, Tiger Global, and T. Rowe Price. "With this latest investment, we will continue to welcome more riders into our Waymo One ride-hailing service in San Francisco, Phoenix, and Los Angeles, and in Austin and Atlanta through our expanded partnership with Uber. We'll also continue advancing the Waymo Driver - our AI-powered autonomous driving system - to support a variety of business applications over time," the company said in a statement. Reference Link

09:43 EDT Citizens & Northern partners with POS provider Clover - C&N has partnered with Clover. This collaboration helps businesses streamline everyday operations, improve customer service, and deliver better overall efficiency. The companies said, "With Clover's advanced technology, small- and medium-sized businesses have an all-in-one solution to manage payments, inventory, and customer interactions. Designed to be user-friendly and adaptable, Clover's POS systems are suitable for a wide range of industries, including retail, restaurants, and service-based businesses, making it easier for local entrepreneurs to focus on what they do best-caring for their customers."

09:41 EDT Top Wealth Group Holding Ltd trading halted, volatility trading pause

09:35 EDT Zoomcar Holdings Inc trading halted, volatility trading pause

09:27 EDT TriNet sees 2025 Insurance Cost Ratio 'similar to 2024' - On the company's earnings call, executives from TriNet stated: "We are operating in a difficult health cost environment and are reacting quickly by leveraging our team and improved processes. We are pricing new business and our renewals to appropriately reflect the current and expected health cost environment as a result of the actions we're taking and have already taken our initial view on our 2025 ICR as similar to 2024."

09:17 EDT Nisun International acquires shares for $552,000 under $15M buyback program - Nisun International Enterprise Development Group announced that the Company has repurchased 39,112 shares of its stock at an average price of $14.1263 per share for total proceeds of $552,508 under its $15M share buyback program, which was announced on October 9. The repurchases of the Company's shares were made on October 17. The repurchases are expected to be accretive to EPS, benefiting existing shareholders as the Company's outstanding shares are reduced. Nisun International plans to continue acquiring shares under the buyback program as part of its ongoing commitment to enhancing shareholder value.

09:14 EDT Tompkins Financial increases quarterly cash dividend to 62c per share - Tompkins Financial announced that its board of directors approved payment of a regular quarterly cash dividend of 62c per share, payable on November 15 to common shareholders of record on November 8. The dividend amount represents an increase of 1c per share, or 1.6% over the dividend paid in the third quarter of 2024, and an increase of 2c per share, or 3.3% over the dividend paid in the fourth quarter of 2023.

09:04 EDT BM Technologies to be acquired by First Carolina Bank for $5.00 per share - BM Technologies entered into a definitive agreement to be acquired by First Carolina Bank pursuant to which First Carolina will purchase all outstanding BMTX shares of common stock for $5.00 per share in an all-cash transaction with an equity value of approximately $67M. Under the terms of the agreement, BM Technologies stockholders will receive $5.00 per share in cash, which represents a 55% premium to the trading price per share of BM Technologies common stock as of October 24, 2024 and a 90% premium to market as of August 14, 2024, the day before BM Technologies disclosed that it had received inbound interest. Upon completion of the transaction, BM Technologies will become a wholly owned subsidiary of First Carolina Bank and shares of BM Technologies' common stock will no longer be listed on the New York Stock Exchange. BM Technologies will continue operating under the BM Technologies name and be led by Jamie Donahue, current President and Chief Technology Officer of BMTX. The merger agreement has been approved by both the Boards of BMTX and First Carolina Bank and is subject to stockholder approval by stockholders of BMTX. The parties expect the transaction to close in the first quarter of 2025, subject to the satisfaction of customary closing conditions.

09:02 EDT Elray Resources announces sale of iGaming technology to 180 Life Sciences - Elray Resources announced a significant milestone in the company's growth strategy. Elray has completed the sale of proprietary technology to 180 Life Sciences Corp. in exchange for preferred stock convertible into a 40% stake in ATNF and warrants to purchase 3 million shares of ATNF common stock, the conversion/exercise of which is subject to stockholder approval. The technology stack contained within Elray's technology package will assist ATNF in launching an iGaming Blockchain casino.

09:01 EDT Arthur J. Gallagher acquires Via Financial Group - Arthur J. Gallagher & Co. announced the acquisition of Sydney, New South Wales-based Via Financial Group. Terms of the transaction were not disclosed. Via Financial Group provides financial planning, wealth management and life risk advisory services to clients from multiple offices in Australia. Matthew Read, Daniel Burden, Peter Kirby, Ben Davis, Robert Wilson, Sam Haydon and their team will join Gallagher under Graham Campbell, head of Gallagher's employee benefits and HR consulting operations in Australia.

08:48 EDT Trinity Biotech acquires EpiCapture for initial $3M consideration - Trinity Biotech announced the acquisition of EpiCapture. This acquisition marks Trinity Biotech's strategic expansion into the oncology diagnostics market. Prostate cancer is the most common non-skin cancer among men in the U.S., with about 1 in 8 men diagnosed during their lifetime and the cost for diagnosis and treatment estimated at over approximately $10B annually. The ability to accurately monitor prostate cancer progression is critical, as the disease can often be slow-growing, and unnecessary invasive interventions, such as prostate biopsies, can lead to significant complications. The EpiCapture test could significantly reduce the frequency of these interventions, thereby improving the quality of life for patients. EpiCapture's urine-based test is designed to reduce the need for repeated invasive prostate biopsies for patients undergoing active surveillance for prostate cancer. The test offers a breakthrough approach to monitoring disease progression by using epigenetic analysis to detect DNA methylation patterns that are indicative of high-grade cancer. A study published in The Journal of Clinical Oncology - Precision Oncology demonstrated that, when combined with the widely used prostate-specific antigen test, EpiCapture's test "correctly predicted all high-grade cancers." Trinity Biotech plans to leverage its 30 years of experience in diagnostic product optimization and manufacturing to commercialize the EpiCapture test in the US while also exploring regulatory pathways for launching the test in additional markets. Trinity Biotech acquired EpiCapture for initial consideration of approximately $3M, with an additional consideration of $0.5M contingent on the achievement of future milestones. The initial consideration was paid through the issuance of approximately 1.7M American Depository Shares in Trinity Biotech. EpiCapture is a spin-out company of NovaUCD, part of University College Dublin.

08:45 EDT FC Private Equity, Telsec Property reject 'take under' offer for Melcor REIT - FC Private Equity Realty Management and Telsec Property Corporation, both long term investors in Melcor Real Estate Investment Trust, reiterate Firm Capital's previous call to unitholders of Melcor REIT to VOTE AGAINST the recently announced going private transaction led by Melcor Developments, the founder, 55% owner, and the external manager of Melcor REIT. As detailed in each of Firm Capital and Telsec's press releases dated September 18, 2024, and October 15, 2024, respectively, the Offerors believe the loss of Unitholder value is the direct result of the neglect of trustee oversight and problematic governance that is only overshadowed by the Take Under Offer, which the Offerors believe represents one of the most egregious cases of failed governance controls by a group of Canadian trustees in recent years. In order to assist the Offerors to block the Take Under Offer and hold management of Melcor REIT accountable, the Offerors are pleased to announce that they will offer to acquire up to 1,296,316 participating trust units of Melcor REIT from holders thereof other than Melcor Developments and any related party of Melcor REIT or Melcor Developments at a price of $4.95 per Trust Unit, payable in cash. Each depositing Minority Unitholder whose Trust Units are taken up and paid for must be a holder of such Trust Units as of the record date for the Meeting. The Tender Price represents a premium of approximately 46% to the last closing price of the Trust Units before the announcement of the Take Under Offer and, unlike the Tender Offer, provides Unitholders an opportunity to liquidate their ownership in Melcor REIT without waiting for the Unitholder vote to approve the Take Under Offer. The Tender Offer is not a formal or exempt take-over bid under Canadian securities laws and regulations and is limited to a maximum of 1,296,316 Trust Units. If the Take Under Offer is defeated, the Offerors are prepared to use their expanded holdings to hold management accountable for their actions and to help ensure the future success of Melcor REIT for the benefit of all Unitholders. To that end, the Offerors have had an opportunity to review a copy of the "Background to the Arrangement" in Melcor REIT's management information circular to be mailed to Unitholders in connection with the Meeting and believe there are substantial, unexplained irregularities in the events and processes leading up to the announcement of the Take Under Offer, which it intends to pursue after the defeat of the Take Under Offer. The Tender Offer is open for acceptance by Minority Unitholders on a rolling "first come, first served" basis until 5:00 p.m. on November 18, 2024, unless the Tender Offer is extended, varied or withdrawn. Deposited Trust Units may be withdrawn at any time prior to the time they are taken up by the Offerors. The Tender Offer is subject to certain terms and conditions as set out in the Tender Offer Documents which, unless waived, must be satisfied. In particular, the Offer Documents provide that each depositing Minority Unitholder whose Trust Units are taken up and paid for must appoint representatives of the Offerors as its nominees and proxies, for the upcoming special meeting of Melcor REIT scheduled to be held on November 26, 2024, and any adjournments or postponements thereof. The Tender Offer is not subject to any financing condition and the Offerors confirm that they have sufficient cash resources to pay for all Trust Units subject to the Tender Offer.

08:37 EDT Catheter Precision announces exercise of warrants for $4.9M in gross proceeds - Catheter Precision announced the entry into a definitive agreement for the immediate exercise of certain outstanding Series E, Series F, Series G, Series H and Series I warrants to purchase up to an aggregate of 5,347,981 shares of the Company's stock at a reduced exercise price of $0.70 for total gross proceeds of approximately $3.7 million. An additional $1,185,000 of gross proceeds were received through the exercise of warrants over the last week in accordance with their original terms. Ladenburg Thalmann & Co. Inc. acted as the exclusive warrant inducement agent for the exercise of the Existing Warrants. In consideration for the immediate exercise of the Existing Warrants, the Company will issue new unregistered Series K warrants to purchase up to 10,695,962 shares of common stock. The new warrants will have an exercise price of $0.70, will be exercisable only after shareholder approval of their exercise has been obtained, and will have a term of 5.5 years from the date of exercisability.

08:36 EDT Upexi to take action against 'apparent stock manipulation' - Upexi announces an issue affecting the Company's shareholders in regard to the recently completed reverse stock split. Prior to the Company's required announcement regarding the reverse stock split on September 27,2024, Upexi estimates there were less than 5,000 shareholders of record. Post-split 5 Brokerage firms have requested roundup shares equaling approximately 199,059 shares of the Company's common stock out of a total of 202,183 round up shares of the Company's common stock requested. The 202,183 roundup shares requested is approximately 19% of the Company's outstanding shares of common stock post-split and represents an increase of approximately 40 times the number of individual shareholders owning the Company's common stock. The foregoing activity appears to have occurred during the 3 day trading period between the reverse split announcement and the effective date of the reverse split. The Company and its legal team are currently reviewing the foregoing trading activity to determine if such activity involved possible stock manipulation.

08:34 EDT Nine Energy Service receives noncompliance notification from NYSE - Nine Energy Service announced that it received written notice from the NYSE on October 21, that the company is not in compliance with the continued listing standards set forth in Section 802.01B of the NYSE Listed Company Manual because its average global market capitalization over a consecutive 30 trading-day period and its last reported stockholders' equity were both below $50M.

08:33 EDT Journey Medical announces presentation of DFD-29 data - Journey Medical (DERM) presented data assessing the dermal and systemic pharmacokinetics of oral DFD-29 versus oral Doxycycline 40 mg capsules in healthy subjects at the 44th Fall Clinical Dermatology Conference that is taking place October 24-27, 2024, in Las Vegas, NV. DFD-29 is being developed for the treatment of rosacea in collaboration with Dr. Reddy's Laboratories (RDY). Claude Maraoui, CEO, stated, "Based on the robust safety and efficacy data seen throughout all our clinical trials, we believe DFD-29 can change the treatment landscape for the millions of patients suffering from rosacea. We submitted a New Drug Application to the U.S. Food and Drug Administration for DFD-29 earlier this year and look forward to the upcoming PDUFA date of November 4, 2024. If approved, DFD-29 has the potential to be the lowest fixed-dose minocycline and the best-in-class therapy for rosacea patients." This randomized, open-label, single-center, parallel-group study evaluated the systemic and dermal PK of once-daily administration of oral DFD-29 40 mg capsules versus oral doxycycline 40 mg for 21 days in healthy adult volunteers. Plasma PK parameters were similar on Day 1 and Day 21 for minocycline, but doxycycline showed accumulation in the plasma with a significant increase in PK parameters from Day 1 to Day 21. Mean dermal Cmax and AUC for minocycline reached maximum levels on Day 1 and remained at a high level until Day 21, while doxycycline started with low levels on Day 1 and attained peak on Day 21. Minocycline had significantly higher levels than doxycycline in the skin both on Day 1 and Day 21. Both DFD-29 and doxycycline were well tolerated by the healthy volunteers.

08:31 EDT Ameresco awarded $2.9M for collaboration with the RUSA - Ameresco announced its collaboration with the Roseburg Urban Sanitary Authority, or RUSA, to implement an energy program. This collaboration aims to enhance the resilience, sustainability, and cost-effectiveness of RUSA's key facilities, including its main office, Wastewater Treatment Plant, and Natural Treatment System. The Oregon Department of Energy has selected 34 recipients to receive nearly $18M in Community Renewable Energy Grant Program funds. With the assistance of Ameresco, RUSA was awarded almost $2.9M in grant funds for three projects.

08:30 EDT Johnson & Johnson reports results from Phase 3b SPECTREM study - Johnson & Johnson announced that treatment with TREMFYA, or guselkumab, resulted in clear or almost clear skin in the majority of adults with low body surface area, or BSA, moderate plaque psoriasis, or PsO, with special site involvement who had failed topical treatment. Sensitive or highly visible areas affected by PsO, including the scalp, face, skin folds and genitals, are considered "special sites" and can have significant impact on patients' daily lives, yet systemic treatment is infrequently provided and this group of patients remains largely undertreated. Data from the Phase 3b SPECTREM study, the first prospective, large-scale, randomized-controlled, double-blind clinical study to measure skin clearance and other treatment outcomes in low BSA moderate PsO with involvement across four special sites and previous topical treatment failure, were presented today at the 2024 Fall Clinical Dermatology Conference. A significantly greater proportion of patients who received TREMFYA achieved the primary endpoint of an Investigator's Global Assessment score of cleared or minimal disease compared to those who received placebo. These results were comparable irrespective of baseline BSA. Significant clearance versus placebo at Week 16: scalp, face, intertriginous and genital. Complete clearance of each special site was consistently achieved in the majority of patients who received TREMFYA versus placebo. Beginning today, healthcare providers will have access to the TREMFYA(R) Clearance Photo Library, an expansive, longitudinal library of before and after treatment photographs from the Phase 3b VISIBLE study. The online resource enables patient images to be filtered based on clinical characteristics, such as disease severity, areas of involvement, and clearance outcomes across all skin tones.

08:21 EDT Golden Matrix's Meridianbet launches AI-powered Bet Recommender - Golden Matrix Group announced the launch of the AI-powered Bet Recommender by its sports betting division Meridianbet. The AI Bet Recommender is designed to offer real-time, personalized betting suggestions, tailored to individual player preferences and habits. By processing thousands of data points from sports events and odds parameters, the AI platform ensures that each bet is informed, timely, and highly relevant to the user. Key features include: Data-Driven Decisions: Utilizing vast sports data and odds to deliver precise betting choices. Tailored Suggestions: Customized bet recommendations aligned with individual user behaviors. Real-Time Adaptability: Offering dynamic, live bet recommendations during events to capture in-play opportunities. Seamless CRM Integration: The AI recommender is fully integrated with top-tier CRM solutions, empowering operators with more effective user engagement and segmentation tools.

08:15 EDT Aspira Women's Health issues letter to shareholders - The Company issued the following letter to Company shareholders from CEO Nicole Sandford. "Yesterday, it was my honor to share news of an exciting development that we believe will shape Aspira Women's Health for many years to come. We have been selected by the Advanced Research Projects Agency for Health as an awardee of the Sprint for Women's Health... Under this initiative, we were awarded $10 million in funding over two years to develop our multi-marker blood test to aid in the detection of endometriosis. Our test will rely on a powerful, AI-enabled algorithm that combines protein and microRNA biomarkers and patient data... The award defines a series of project milestones, the first of which we expect to meet in the fourth quarter of 2024. Upon successful acceptance of the required information related to the first milestone, Aspira will receive a payment of $2 million. The award also provides for access to a team of world-class subject matter experts and advisors to support the successful completion and commercial launch of the test before the end of the two-year contract term... Aspira was selected as one of 23 awardees from a field of over 1,700 submissions.... This is an incredible achievement and validation of Aspira's capabilities... Now the hard work really begins! We will work with the ARPA-H team to perform an assessment and detailed analysis of execution risks."

08:11 EDT Ellington Residential announces ISS recommends shareholders vote for proposals - Ellington announced that Institutional Shareholder Services, or ISS, became the second leading independent proxy advisory firm, joining Glass Lewis, to recommend that shareholders of the company vote for the proposals set forth by the board of trustees of the company that would allow the company to complete its conversion to a closed-end investment company registered under the Investment Company Act of 1940, as amended, which would be treated as a regulated investment company under the Internal Revenue Code of 1986, as amended.

08:10 EDT Yoshitsu signs five-year strategic cooperation agreement with Saynoday - Yoshitsu announced that on October 16, the Company, through its wholly-owned Hong Kong subsidiary Tokyo Lifestyle entered into a five-year strategic cooperation agreement with Saynoday. This partnership aims to further expand the market presence of Yoshitsu's proprietary "Reiwatakiya" brand in Hong Kong and other key Asian markets. The Agreement reflects the high level of mutual trust between both parties and their confidence in exploring growth opportunities within the beauty and daily necessities sectors in Asia. Pursuant to the Agreement, Yoshitsu and Saynoday agree to deepen the existing trademark licensing and product supply cooperation in which Yoshitsu has granted Saynoday the right to use the "Reiwatakiya" brand. Under the Agreement, Saynoday commits to procuring high-quality cosmetics and daily necessities from Tokyo Lifestyle, totaling 500 million Hong Kong dollars over the next two years, following an initial procurement of 100 million Hong Kong dollars over the past two years under their current cooperation. Both parties agree to collaborate on brand promotion through resource integration, including optimizing the brand's official website and expanding online sales channels and promotional strategies. Furthermore, leveraging Tokyo Lifestyle's successful operation of multiple stores in Hong Kong, Saynoday plans to open five new "Reiwatakiya" stores by the end of 2027, with new stores opening each year in strategic shopping districts, including Mong Kok, Tuen Mun, Hong Kong International Airport, and Kowloon. This expansion will add to its two existing franchise stores in Tsuen Wan and Admiralty, further boosting the brand's visibility and market penetration in Hong Kong.

08:08 EDT Acasti Pharma announces corporate name change to Grace Therapeutics - Acasti Pharma announced that it is changing its name to Grace Therapeutics. Grace Therapeutics was the name of the company developing GTx-104 prior to its merger with Acasti in 2021. Grace Therapeutics will begin trading on Nasdaq under the trading symbol "GRCE" at the open of the market on October 28, 2024 and all company branding including corporate website will be updated accordingly. "The Grace Therapeutics brand reconnects us to our roots that are steeped in scientific innovation and highlights our transformative journey," said Prashant Kohli, CEO. "The breakthrough formulation of GTx-104 is the result of a decade of research by our exceptional scientific team while Grace Therapeutics was located in the pharma industry research corridor of New Jersey. We have continued to make significant progress in the clinical development plan of GTx-104, including full enrollment of the STRIVE-ON trial and anticipate a data readout in early calendar 2025 with an expected submission of a New Drug Application to the U.S. Food and Drug Administration in the first half of calendar 2025. In addition to advancing GTx-104 over the past 18 months, we successfully restructured to an agile biopharma model, rebuilt the management team, prioritized the pipeline, divested legacy assets, strengthened the balance sheet, and re-domiciled to the United States as a Delaware corporation. We believe these steps offer several potential benefits, including a U.S. corporate structure that should increase the company's attractiveness and marketability to potential strategic partners and global institutional investors. We are proud of the progress made within a relatively short timeframe and look forward to fully realizing the Company's value under the Grace Therapeutics brand."

08:04 EDT Aquestive to present subsequent analysis of data from Anaphylm study - Aquestive Therapeutics announced that a subsequent analysis of the data from the pivotal study of its product candidate Anaphylm Sublingual Film demonstrating comparable PK and PD data regardless of variable placement or intraoral movement will be presented at the American College of Allergy Asthma and Immunology annual meeting, which is being held from October 24-28 in Boston, Massachusetts."The poster, detailing a subsequent analysis of the data from the pivotal study of Anaphylm, being presented at ACAAI this year marks an important milestone in our development of Anaphylm, as it demonstrates the robustness and reliability of our sublingual film technology," said Dan Barber, Aquestive's CEO, "These findings show that our innovative PharmFilm delivery system maintains consistent pharmacokinetics and pharmacodynamics regardless of minor variations in placement, providing further evidence of Anaphylm's potential to offer healthcare providers and patients a dependable alternative for the treatment of severe allergic reactions. Anaphylm has the potential to be the first and only FDA-approved no-needle, no-device, oral epinephrine product for treating severe allergic reactions, including anaphylaxis, if approved by the FDA." The poster presentation will showcase a subsequent analysis of the previously disclosed pivotal study that successfully met primary and secondary endpoints, found at the link here. The subsequent analysis was conducted to evaluate the impact of intraoral film placement and movement on variability in PK and PD. Movement was noted in 12.5% of subjects. Results of the pivotal study demonstrated consistent drug delivery, with 87.5% of subjects showing no change in film location between 1.5 to 3 minutes after administration of Anaphylm. In cases where movement was noted, there were no significant differences between subjects with or without film movement in geometric mean maximum concentration, or Cmax, or median peak drug concentration, or Tmax. These findings support that the initial placement or subsequent movement of the sublingual film had no impact on epinephrine PK or PD, with all results comparable to epinephrine injection.

07:36 EDT ZenaTech promotes team members in sales, customer support, administration - ZenaTech announces the promotion of several team members in the sales, customer support, and administration areas of its ZenaDrone drone business division, and its enterprise SaaS software division. Philander Franklin, Vice President of Business Development for the Americas. Philander will focus on North American drone business sales and building our Arizona operations and manufacturing base. He has worked with ZenaTech-associated businesses and ZenaDrone, for the last nine years in various capacities leading the expansion of sales, operations, customer and partner relationships, and operations support. Simon Henry, Vice President of Business Development for EMEA. Simon will focus on building our drone sales in the EMEA region as well as further building our operations base in Ireland. He has worked with ZenaDrone for over three years, leading drone pilot programs and sales and partnerships in Europe. Steve Rhode, Director of Software Sales and Customer Support. Steve will focus on sales and customer support strategy and implementation for ZenaTech's Enterprise SaaS software division. He has worked with ZenaTech-associated SaaS companies for over 10 years in various sales, technical, and project management roles. Lindsey Bartholomew, Director of Administration. Lindsey will focus on building the administrative infrastructure and support for ZenaTech's portfolio of companies. Lindsey has worked with ZenaTech-associated companies for over three years in various accounting, administration, operations management, and mergers and acquisition administration roles.

07:35 EDT Territorial Bancorp says Glass Lewis recommends shareholders vote 'for' merger - Territorial Bancorp (TBNK) announced that leading independent proxy advisory firm Glass, Lewis & Co has joined Institutional Shareholder Services, ISS, in recommending that Territorial shareholders vote "FOR" the Company's pending merger with Hope Bancorp (HOPE).Commenting on the Glass Lewis and ISS reports, Territorial issued the following statement: "The Territorial Board of Directors and management team collectively own 9.2% of Territorial's outstanding shares. We are confident that the Hope Bancorp transaction is the best path forward for Territorial, our shareholders, customers, employees and the local communities we serve. We have already voted all of our shares FOR the transaction, and we urge our fellow Territorial shareholders to join us and also follow the recommendations from the Territorial Board, Glass Lewis and ISS by voting FOR the Hope Bancorp transaction today."

07:32 EDT Base Carbon receives second transfer of carbon credits from Rwanda project - Base Carbon has received a second transfer of 1,014,635 carbon credits from its Rwanda project, each designated with Verra's Article 6 Authorized label. Highlights: Received second transfer of 1,014,635 Article 6 Authorized labeled carbon credits from the Rwanda project. The Company now holds a current inventory of 1,712,193 Article 6 Authorized labeled carbon credits generated from the Rwanda project. Pursuant to the terms of the project agreement with the DelAgua Group, the project developer, and the letter of authorization issued by the Government of Rwanda with respect to the project, the Company has received a transfer of 1,014,635 Article 6 Authorized labeled carbon credits. This volume is net of 23,060 carbon credits which have been retired to contribute towards global emission reductions and 115,300 carbon credits to be made available to the Government of Rwanda pursuant to the terms of the LOA. The Company now holds a total inventory of 1,712,193 carbon credits generated from the Rwanda project, all designated with Verra's Article 6 Authorized label.

07:25 EDT Purple Biotech presents data for tri-specific antibody platform CAPTN-3 - Purple Biotech announced new data regarding its tri-specific antibody platform, CAPTN-3, which were presented at the 36th European Organization for Research and Treatment of Cancer, National Cancer Institute, American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics on October 25, 2024 in Barcelona, Spain. CAPTN-3 is a novel platform technology of conditionally activated tri-specific antibodies engaging both T cells and NK cells to target cancers expressing Tumor Associated Antigen to induce a strong and selective immune response against the tumor. The addition of the NK engager aims to enhances the tumor-killing activity, providing a key differentiation for more sustained and potent anti-tumor effects. The anti-NKG2A arm also acts as a checkpoint inhibitor enabling simultaneous NK and T-cell activation. This scaffold is designed to be activated only at the tumor microenvironment to improve the safety profile and extend the therapeutic index. The capped-alphaCD3 is cleaved by multiple TME-specific proteases, increasing the likelihood of activation by various tumor types. To further extend the capped tribody half-life, human serum albumin is included. CAPTN-3 leverages a plug and play scaffold system providing a flexible design to easily swap and integrate various antibodies to target a wide range of diseases. The platform's lead compound IM1240 targets 5T4, a TAA expressed in a variety of solid tumors and which is correlated with advanced disease, increased invasiveness, and poor clinical outcome. Purple Biotech's poster titled "CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers", presented the following: The lead compound, IM1240 demonstrated high affinity binding towards CD3 & NKG2A proteins and CD3 & NKG2A expressing cells, while no binding was detected using the mutated versions of the tribody, indicating specificity. The synergistic effects of the alphaCD3 and alphaNKG2A arms in suppressing 5T4+ non-small cell lung cancer patient-derived explant at 10nM were demonstrated, emphasizing CAPTN-3's potential advantage in a clinically-relevant biological assay. A dose-dependent effect of IM1240 was shown. Sustained tumor regression in triple negative breast cancer humanized mice was demonstrated for the capped tribody, which was superior to the uncapped tribody. No effect was shown with the non-cleavable capped tribody whose CD3 binding function is irreversibly blocked. Cytotoxic effect and binding to CD3 was fully recovered following capping cleavage. PBMC-mediated cytotoxicity against 5T4+ cancer cells was demonstrated at picomolar EC50 while no effect was observed in 5T4- cancer cells. IM1240 and non-capped tribody inhibited NKG2A-HLA-E interaction in a dose-dependent manner, while NKG2A mutated tribody had no effect. NK cell mediated cytotoxicity against HLA-E expressing cancer cells was demonstrated, while NKG2A mutated tribody had no effect. A cytokine release assay from hPBMC showed a 5T4+ cancer cell dependency and was inhibited by the cap, showing superior safety profile. Plug and Play abilities of the platform were demonstrated through different tribodies targeting 5T4, EGFR and NKG2D which demonstrated low nM and selective binding to cells overexpressing the target, and efficient PBMC and NK mediated cytotoxicity.

07:05 EDT Colgate-Palmolive reports Q3 base profit margin up 270 bps to 61.3% - Reports Q3 GAAP gross profit margin increased 260 basis points to 61.1%. Colgate's leadership in toothpaste continued with its global market share at 41.6% year to date. Colgate's leadership in manual toothbrushes continued with its global market share at 32.3% year to date.

07:02 EDT Silvaco Inc. achieves ISO 9001 certification - Silvaco Group announced that its wholly-owned subsidiary Silvaco, Inc. has obtained ISO 9001 certification of its quality management system to support its TCAD, EDA software, and SIP solutions. The certification underscores Silvaco's ongoing commitment to quality, customer satisfaction, and continuous improvement across its entire portfolio products. The certification was performed by Schellman Compliance, LLC, an ANAB accredited Certification Body based in the United States.

07:01 EDT Aaon announces orders totaling $174.5M - AAON announces it was recently awarded orders from one data center customer that approximately totaled $174.5M. Under these orders, AAON will provide a custom-designed thermal management system supporting a liquid cooling deployment for the customer's data centers. The equipment will be manufactured under our BASX brand in our existing and newly constructed facilities at our Longview, Texas location and is expected to mostly be produced and delivered in the first half of 2025. The construction of the new facility is on schedule to be completed by the end of this year and the Company has already begun staffing, training and setting up the operations in preparation for production to commence in early 2025.

06:52 EDT ANI Pharmaceuticals announces FDA approval of Estradiol Gel, 0.06% - ANI Pharmaceuticals announced that following final approval from the U.S. FDA for its Abbreviated New Drug Application, the company launched Estradiol Gel, 0.06%. ANI's Estradiol Gel, 0.06% is the generic version of the reference listed drug EstroGel Gel, 0.06%. U.S. annual sales for Estradiol Gel, 0.06% total approximately $16.7M, based on August 2024 moving annual total (MAT) IQVIA data.

06:51 EDT Eli Lilly presents new Ebglyss data at FCD Conference - New results show Eli Lilly's Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results from the Phase 3b ADapt study will be presented at the Fall Clinical Dermatology, or FCD, Conference from Oct. 24-27 in Las Vegas. The ADapt study evaluated the efficacy and safety of Ebglyss in patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. To qualify for ADapt, patients must have discontinued dupilumab treatment due to inadequate response, intolerance or an adverse event, or other reasons. The primary endpoint of the study was measured by at least 75% improvement in the Eczema Area and Severity Index, or EASI-75, score at 16 weeks, which evaluates the extent and severity of the skin disease. Secondary endpoints at 16 and 24 weeks included Investigator Global Assessment, or IGA, score of clear or almost clear skin with a reduction of at least two points from baseline and at least a four-point improvement in Pruritus NRS from baseline. Other secondary and exploratory endpoints were also included. The reported endpoints were as observed. With Ebglyss, 57% of patients at Week 16, and 60% of patients at Week 24 who were previously treated with dupilumab, achieved EASI-75. These results are similar to what was observed in the Phase 3 monotherapy trials of Ebglyss in patients without prior exposure to dupilumab. In addition, 46% of patients who were inadequate responders to dupilumab achieved EASI-75 response with Ebglyss at Week 16. Fifty-three percent and 62% of ADapt patients who discontinued dupilumab and began treatment with Ebglyss also experienced itch relief with at least a four-point improvement from baseline at Week 16 and Week 24 respectively. Patients in this study saw improvements in difficult-to-treat areas when treated with Ebglyss. More than half of patients treated with Ebglyss saw clear or almost clear face dermatitis at Week 24 (F-IGA 0,1 with a reduction of at least two points from baseline). Among patients with moderate-to-severe hand dermatitis at baseline, patients' modified total lesion symptom score, which measures extent and severity of hand dermatitis, decreased by 75% at Week 24.1. Less than six percent of patients treated with Ebglyss experienced an adverse event that led to treatment discontinuation. The safety profile of Ebglyss in ADapt was consistent with previous Ebglyss Phase 3 studies in patients with moderate-to-severe atopic dermatitis, and no new safety signals were observed. The majority of adverse events were mild or moderate. Reported treatment-related side effects in the study were conjunctivitis and injection site reactions. Of the 14 patients who discontinued dupilumab due to an adverse event, two patients discontinued Ebglyss due to an adverse event. Of the 10 patients who discontinued dupilumab due to eye-related events, facial dermatitis or inflammatory arthritis, none reported similar events with Ebglyss .

06:32 EDT Barnes Group suspends financial guidance for 2024 - Given the pending acquisition of Barnes by Apollo Funds, the company will not be conducting a third quarter 2024 conference call and webcast. In addition, Barnes is suspending its financial guidance for the full year 2024.

06:27 EDT NatWest Group expects 2026 return on tangible equity greater than 13% - In 2026, the company continues to expect: to achieve a return on tangible equity for the Group of greater than 13%.

06:14 EDT Ideaya Biosciences announces IDE397 expansion data - Ideaya Biosciences announced Phase 1 expansion data for IDE397 in methylthioadenosine phosphorylase, or MTAP-deletion urothelial cancer, or UC, and non-small cell lung cancer, or NSCLC, patients as a late breaker abstract, or LBA, oral presentation at the 36th edition of the EORTC-NCI-AACR Symposium, or ENA 2024, in Barcelona, Spain. In addition, IDEAYA had additional poster presentations at ENA 2024 highlighting preclinical data for the MAT2A and PARG programs. IDE397 is a potent and selective potential first-in-class methionine adenosyltransferase 2 alpha, or MAT2A, inhibitor in Phase 2 clinical trials for the treatment of MTAP-deletion solid tumors. The company observed encouraging clinical activity at the 30 mg once-a-day Recommended Phase 2 Dose in its Phase 1 clinical trial evaluating its MAT2A inhibitor IDE397 in heavily pre-treated MTAP-deletion UC and NSCLC patients. The patients evaluated had a median of two to three prior lines-of-therapy, ranging from one to seven. The reported Phase 1 clinical expansion data are based on 27 evaluable MTAP-deletion patients, including ten UC, nine adenocarcinoma NSCLC, and eight squamous NSCLC patients at the expansion dose of 30 mg QD of IDE397. The clinical efficacy and tolerability data are preliminary and based on investigator review from an unlocked database as of the data analysis cutoff date of August 22. The clinical data update in the twenty-seven evaluable patients by RECIST 1.1 include: 33% overall response rate, or ORR. One complete response and eight partial responses by RECIST 1.1 evaluation out of 27 evaluable patients. Nine of nine responses have been confirmed by RECIST 1.1, including four UC patients, of which one was a CR, three squamous NSCLC patients, and two adenocarcinoma NSCLC patients. Two patients confirmed after the data cutoff date. In the earlier reported July 82, IDE397 webcast program update, five confirmed responses were reported out of eighteen evaluable patients. There were zero non-evaluable patients reported as of the data analysis. Confirmed ORR% by RECIST 1.1 by Solid Tumor Type: MTAP-deletion UC =40% confirmed ORR%; MTAP-deletion squamous NSCLC ~38% confirmed ORR%; MTAP-deletion adenocarcinoma NSCLC = 22% confirmed ORR%. Multiple confirmed partial responses by RECIST 1.1 harbor genetic co-alterations, including MTAP-deletion and KRAS G12D mutation in NSCLC, and MTAP-deletion and FGFR-TACC3 fusion in UC, 93% Disease Control Rate. One CR, eight PRs, and sixteen stable disease by RECIST 1.1 evaluation out of twenty-seven evaluable patients. Preliminary durability assessment: Fifteen of twenty-seven patients still on treatment. Seven of nine RECIST 1.1 responses remain on treatment. Median duration of treatment has not been reached and is greater than 6.2 months and median time to response is 2.7 months. The median duration of response and median progression free survival data is still immature. Three UC patients on treatment greater than 250 days, four squamous NSCLC patients on treatment greater than 200 days, and three adenocarcinoma NSCLC patients on treatment greater than 200 days 81% ctDNA Molecular Response Rate. Seventeen of twenty patients with 50% or greater ctDNA reduction, and 33% with deep 90% or greater ctDNA reduction. All MRs were rapid occurring at the first ctDNA sample analysis. There were several quality control failures of patient samples that led to unavailability for MR analysis. Favorable adverse event profile. Approximately 18% grade 3 or higher drug-related AEs and no drug-related serious adverse events observed at the IDE397 30mg once-a-day expansion dose. No drug-related AEs leading to discontinuations were observed. The company anticipates that the favorable AE profile and dosing convenience of a 30 mg once-a-day tablet has the potential to enable long-term dosing and combination development, including with MTA-cooperative PRMT5 inhibitors and topoisomerase payload antibody drug conjugates. Ideaya reports the first preliminary clinical case study of the IDE397 and Trodelvy combination in MTAP-deletion UC, including a PR by RECIST 1.1 in a patient case report with a genetic co-alteration of MTAP-deletion and a FGFR3-TACC3 fusion, and rapid and deep first-evaluation molecular responses with ctDNA reduction of greater than 95% observed that will be presented at ENA 2024. IDEAYA is targeting to initiate the IDE397 and Trodelvy Phase 1/2 combination expansion in MTAP-deletion UC in Q4 2024. Ideaya has activated over 35 clinical trial sites globally in the U.S., Canada, Europe, and Asia Pacific to enable potential rapid enrollment for the IDE397 Phase 2 monotherapy expansion in MTAP-deletion lung and bladder cancer in its ongoing trial. There is also an ongoing Amgen-sponsored Phase 1/2 trial of the IDE397 and AMG 193 combination in MTAP-Deletion NSCLC. Ideaya published at ENA 2024 preclinical combination efficacy data and the combination mechanistic rationale for IDE397 with clinical stage PRMT5 inhibitors, including BMS-986504 and AMG 193. Next, Ideaya is enrolling a Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of IDE397 in combination with Trodelvy in MTAP-deletion UC patients. Pursuant to the clinical study collaboration and supply agreement, Ideaya and Gilead retain the commercial rights to their respective compounds, including with respect to use as a monotherapy or combination agent. Ideaya is the study sponsor and Gilead will provide the supply of Trodelvy to IDEAYA. IDE397 monotherapy or in combination with Trodelvy has not been approved by any regulatory agency and the efficacy and safety of this combination has not been established.

05:22 EDT Faraday Future signs development pact for future Ras Al Khaimah headquarters - Faraday Future has officially announced a co-investment agreement with Master Investment Group, owned by Sheikh Abdulla Al Qassimi, a member of the royal family and deputy chairman of customs in Ras Al Khaimah. This collaboration is for the development of the company's future headquarters in Ras Al Khaimah, a region within the United Arab Emirates, or UAE. This development signifies the progression of Faraday Future into the operational phase following the launch of its Middle East strategy last November, facilitating operational and sales activities within the UAE. Master Investment Group aims to commence construction in Ras Al Khaimah by the end of this year and the company aims to occupy the premises by late 2025 or early 2026. Tin Mok, the Head of FF UAE, representing Faraday Future Middle East, has signed a lease agreement with the Ras Al Khaimah Economic Zone, or RAKEZ, for a business location that will include office space and an engineering workshop. Matthias Aydt, the global CEO of Faraday Future, has signed a reservation agreement with RAKEZ for an in-construction facility of 108,000 square feet, which will serve as a future operational hub.

05:15 EDT Revolution Medicines presents initial data from RMC-9805 study - Revolution Medicines announced preliminary safety and antitumor data for RMC-9805, its RAS G12D-selective inhibitor, in patients with previously treated pancreatic ductal adenocarcinoma, or PDAC. These initial results were presented during the late-breaking oral session at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona on October 25. The RMC-9805-001 Phase 1/1b study is a multicenter, open-label, dose-escalation and dose-expansion study designed to evaluate RMC-9805 in patients with advanced solid tumors harboring a KRAS G12D mutation. As of the September 2 data cutoff date, 179 patients were treated with escalating doses of RMC-9805. Study patients had received a median of two prior therapies and all had previously been treated with standard of care. As of the data cutoff date, RMC-9805 demonstrated an encouraging safety profile and was generally well tolerated across dose levels. For patients receiving 1200 mg of RMC-9805 daily, the most common treatment-related adverse events, or TRAEs, occurring in greater than 10% of patients were GI-related toxicities and rash that were primarily Grade 1 in severity and typically of limited duration. One Grade 3 TRAE of ALT elevation was reported, and no Grade 4 or 5 TRAEs were observed. Four patients experienced TRAEs that led to dose reduction and no patients discontinued treatment as a result of TRAEs. No dose limiting toxicities were observed and the maximum tolerated dose was not reached. Preliminary efficacy was assessed in PDAC patients. At a candidate recommended Phase 2 dose of 1200 mg daily, patients who received a first dose of RMC-9805 at least 14 weeks prior to the data cutoff date achieved a 30% objective response rate, with a disease control rate of 80%.